| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-10-21 | NeuroVive Pharmaceutical (Sweden) OnCore Biopharma, now Arbutus Biopharma (USA - PA) | NVP018 (second-generation cyclophilin inhibitor) | hepatitis B | licensing |
Infectious diseases | Termination of an agreement |
| 2016-10-20 | Sotio (Czech Republic) NBE Therapeutics (Switzerland) | next-generation antibody-drug conjugates against undisclosed targets | licensing collaboration |
Cancer - Oncology | Licensing agreement | |
| 2016-10-20 | Spark Therapeutics (USA - PA) University of Massachusetts Medical School (USA - MA) | adeno-associated virus (AAV) vectors | collaboration R&D |
Ophtalmological diseases - Hepatic diseases - Liver diseases -CNS diseases | Collaboration agreement | |
| 2016-10-19 | Txcell (France) University of British Columbia (UBC) (Canada) | CAR-Treg-based cellular immunotherapy | prevention of graft rejection | R&D collaboration |
Transplantation | R&D agreement |
| 2016-10-19 | Pfenex (USA - CA) | nomination |
Nomination | |||
| 2016-10-19 | Merus (The Netherlands) Ono Pharmaceutical (Japan) | bispecific antibodies | R&D - research - licensing | Autoimmune diseases | Milestone | |
| 2016-10-18 | Polyphor (Switzerland) | nomination |
Nomination | |||
| 2016-10-17 | Apitope (UK) Merck KGaA (Germany) | ATX-MS-1467 | multiple sclerosis | R&D |
Neurodegenerative diseases | Termination of the agreement |
| 2016-10-14 | Acticor Biotech (France) Mediolanum farmaceutici (Italy) | ACT017 | acute ischemic stroke | R&D development |
Cardiovascular diseases - Cerebrovascular diseases | R&D agreement |
| 2016-10-13 | Txcell (France) | nomination |
Autoimmune diseases – Inflammatory diseases - Digestive diseases | Nomination | ||
| 2016-10-13 | Kite Pharma (USA - CA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2016-10-12 | Ablynx (Belgium) Merck&Co (USA - NJ) | Nanobody® candidates directed towards a voltage gated ion channel | undisclosed | R&D - development - commercialisation | undisclosed | R&D agreement |
| 2016-10-12 | Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) Abbott (USA - IL) | companion diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients | acute myeloid leukemia (AML) | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2016-10-12 | Neovacs (France) Cochin Hospital (France) | IFN alpha-Kinoid | type 1 diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2016-10-12 | Inovio Pharmaceuticals (USA - PA) | nomination | Cancer - Oncology - Infectious diseases | Nomination | ||
| 2016-10-11 | Kymab (UK) EpimAb Biotherapeutics (China) | bispecific antibodies | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-10-11 | Curevac (Germany) | nomination |
Nomination | |||
| 2016-10-11 | Merck KGaA (Germany) Pfizer (USA - NY) Transgene (France) | TG4001 in combination with avelumab | human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy | collaboration - clinical research | Cancer - Oncology | Clinical research agreement |
| 2016-10-10 | Hybrigenics (France) Servier (France) | new targets among deubiquitinating enzymes - ubiquitin-specific proteases (USPs) and their inhibitors | research - R&D - licensing | Cancer - Oncology - CNS diseases - Psychiatric diseases - Rheumatic diseases - Ophthalmological diseases - Metabolic diseases - Cardiovascular diseases | Milestone | |
| 2016-10-10 | Medivir (Sweden) | restructuring |
Cancer - Oncology - Infectious diseases | Restructuring |
